» Articles » PMID: 28480295

Variation in Tularemia Clinical Manifestations-Arkansas, 2009-2013

Overview
Date 2017 May 9
PMID 28480295
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: , although naturally occurring in Arkansas, is also a Tier 1 select agent and potential bioterrorism threat. As such, tularemia is nationally notifiable and mandatorily reported to the Arkansas Department of Health. We examined demographic and clinical characteristics among reported cases and outcomes to improve understanding of the epidemiology of tularemia in Arkansas.

Methods: Surveillance records on all tularemia cases investigated during 2009-2013 were reviewed.

Results: The analytic dataset was assembled from 284 tularemia reports, yielding 138 probable and confirmed tularemia cases during 2009-2013. Arthropod bite was identified in 77% of cases. Of 7 recognized tularemia manifestations, the typhoidal form was reported in 47% of cases, approximately double the proportion of the more classic manifestation, lymphadenopathy. Overall, 41% of patients were hospitalized; 3% died. The typhoidal form appeared to be more severe, accounting for the majority of sepsis and meningitis cases, hospitalizations, and deaths. Among patients with available antibiotic data, 88% received doxycycline and 12% received gentamicin.

Conclusions: Contrary to expectation, lymphadenopathy was not the most common manifestation observed in our registry. Instead, our patients were more likely to report only generalized typhoidal symptoms. Using lymphadenopathy as a primary symptom to initiate tularemia testing may be an insensitive diagnostic strategy and result in unrecognized cases. In endemic areas such as Arkansas, suspicion of tularemia should be high, especially during tick season. Outreach to clinicians describing the full range of presenting symptoms may help address misperceptions about tularemia.

Citing Articles

Intracellular but not undetectable: A case of pericarditis.

Bergeron N, Gmehlin C, Akhtar H, Barrett K, Inglis S, Sinak L IDCases. 2025; 39:e02145.

PMID: 39866373 PMC: 11759641. DOI: 10.1016/j.idcr.2024.e02145.


Vector-Borne Zoonotic Lymphadenitis-The Causative Agents, Epidemiology, Diagnostic Approach, and Therapeutic Possibilities-An Overview.

Orsolic M, Sarac N, Topic M Life (Basel). 2024; 14(9).

PMID: 39337966 PMC: 11433605. DOI: 10.3390/life14091183.


Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia.

Hahn M, Triplett C, Anderson M, Smart J, Litherland K, Keech S Antibiotics (Basel). 2023; 12(8).

PMID: 37627757 PMC: 10451734. DOI: 10.3390/antibiotics12081337.


An 8-Month-Old Girl with Prolonged Fever.

Abdo F, Bshouty C, Coffey C, Wittler R Kans J Med. 2021; 14:184-185.

PMID: 34262640 PMC: 8274811. DOI: 10.17161/kjm.vol1415208.


A case of ulceroglandular tularemia presenting with lymphadenopathy and an ulcer on a linear morphoea lesion surrounded by erysipelas.

Balestra A, Bytyci H, Guillod C, Braghetti A, Elzi L Int Med Case Rep J. 2018; 11:313-318.

PMID: 30519119 PMC: 6237246. DOI: 10.2147/IMCRJ.S178561.

References
1.
Dana A . Diagnosis and treatment of tick infestation and tick-borne diseases with cutaneous manifestations. Dermatol Ther. 2009; 22(4):293-326. DOI: 10.1111/j.1529-8019.2009.01244.x. View

2.
Weber I, Turabelidze G, Patrick S, Griffith K, Kugeler K, Mead P . Clinical recognition and management of tularemia in Missouri: a retrospective records review of 121 cases. Clin Infect Dis. 2012; 55(10):1283-90. DOI: 10.1093/cid/cis706. View

3.
Jacobs R, Narain J . Tularemia in children. Pediatr Infect Dis. 1983; 2(6):487-91. DOI: 10.1097/00006454-198311000-00019. View

4.
Ellis J, Oyston P, Green M, Titball R . Tularemia. Clin Microbiol Rev. 2002; 15(4):631-46. PMC: 126859. DOI: 10.1128/CMR.15.4.631-646.2002. View

5.
Mason W, EIGELSBACH H, Little S, Bates J . Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am Rev Respir Dis. 1980; 121(1):39-45. DOI: 10.1164/arrd.1980.121.1.39. View